Seasonal Influenza Vaccine Market in Asia-Pacific to 2018 – Positive Impact of Government Support Offset by Limited Production Capacity, High Investment and Strict Regulations as Barriers to New Entrants...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 11
2 Introduction 13
3 Seasonal Influenza Vaccine Market in Asia-Pacific – Market Overview 14
3.1 Market Characterization and Forecasts 14
3.2 Revenue by Geographical Segmentation 15
4 Seasonal Influenza Vaccine Market in Asia-Pacific – Australia 17
4.1 Registration Process and Regulations 17
4.2 Market Characterization and Forecasts 20
4.3 Cost of Vaccination 21
4.4 Vaccination Pattern 22
4.4.1 Population 22
4.4.2 Vaccinated Population Contribution 23
4.4.3 Vaccination Coverage 24
4.4.4 Number of Doses per Person 24
4.4.5 Total Number of Doses 25
4.4.6 Dose Contribution 25
4.5 Drivers and Barriers 26
4.5.1 Drivers 26
4.5.2 Restraints 26
5 Seasonal Influenza Vaccine Market in Asia-Pacific – China 27
5.1 Registration Process and Regulations 27
5.2 Market Characterization and Forecasts 29
5.3 Cost of Vaccination 30
5.4 Vaccination Pattern 31
5.4.1 Population 31
5.4.2 Vaccinated Population Contribution 32
5.4.3 Vaccination Coverage 33
5.4.4 Number of Doses per Person 33
5.4.5 Total Number of Doses 34
5.4.6 Dose Contribution 34
5.5 Competitive Landscape 35
5.6 Drivers and Barriers 35
5.6.1 Drivers 35
5.6.2 Barriers 35
6 Seasonal Influenza Vaccine Market in Asia-Pacific – Hong Kong 36
6.1 Registration Process and Regulations 36
6.2 Market Characterization and Forecasts 38
6.3 Cost of Vaccination 39
6.4 Vaccination Pattern 40
6.4.1 Population 40
6.4.2 Vaccinated Population Contribution 41
6.4.3 Vaccination Coverage 42
6.4.4 Number of Doses per Person 42
6.4.5 Total Number of Doses 43
6.4.6 Dose Contribution 43
6.5 Competitive Landscape 44
6.6 Drivers and Barriers 45
6.6.1 Drivers 45
6.6.2 Restraints 45
7 Seasonal Influenza Vaccine Market in Asia-Pacific – India 46
7.1 Registration Process and Regulations 46
7.2 Market Characterization and Forecasts 49
7.3 Cost of Vaccination 50
7.4 Drivers and Barriers 51
7.4.1 Drivers 51
7.4.2 Barriers 51
8 Seasonal Influenza Vaccine Market in Asia-Pacific – Japan 52
8.1 Registration Process and Regulations 52
8.2 Market Characterization and Forecasts 54
8.3 Cost of Vaccination 55
8.4 Vaccinated Population 56
8.4.1 Population 56
8.4.2 Vaccinated Population Contribution 57
8.4.3 Vaccination Coverage 58
8.5 Drivers and Restraints 60
8.5.1 Drivers 60
8.5.2 Barriers 61
9 Seasonal Influenza Vaccine Market in Asia-Pacific – Malaysia 62
9.1 Registration Process and Regulations 62
9.2 Market Characterization and Forecasts 64
9.3 Cost of Vaccination 65
9.4 Vaccination Pattern 66
9.4.1 Population 66
9.4.2 Vaccinated Population Contribution 67
9.4.3 Vaccination Coverage 68
9.4.4 Number of Doses per Person 68
9.4.5 Total Number of Doses 69
9.4.6 Dose Contribution 69
9.5 Competitive Landscape 70
9.6 Drivers and Barriers 71
9.6.1 Drivers 71
9.6.2 Barriers 71
10 Seasonal Influenza Vaccine Market in Asia-Pacific – New Zealand 72
10.1 Registration Process and Regulations 72
10.2 Market Characterization and Forecasts 74
10.3 Cost of Vaccination 75
10.4 Vaccination Pattern 76
10.4.1 Population 76
10.4.2 Vaccinated Population Contribution 77
10.4.3 Vaccination Coverage 78
10.4.4 Number of Doses per Person 78
10.4.5 Total Number of Doses 79
10.4.6 Dose Contribution 79
10.5 Competitive Landscape 80
10.6 Drivers and Barriers 81
10.6.1 Drivers 81
10.6.2 Barriers 81
11 Seasonal Influenza Vaccine Market in Asia-Pacific – Philippines 82
11.1 Registration Process and Regulations 82
11.2 Market Characterization and Forecasts 84
11.3 Cost of Vaccination 85
11.4 Vaccination Pattern 86
11.4.1 Population 86
11.4.2 Vaccinated Population Contribution 87
11.4.3 Vaccination Coverage 88
11.4.4 Number of Doses per Person 88
11.4.5 Total Number of Doses 89
11.4.6 Dose Contribution 89
11.5 Competitive Landscape 90
11.6 Drivers and Barriers 91
11.6.1 Drivers 91
11.6.2 Restraints 91
12 Seasonal Influenza Vaccine Market in Asia-Pacific – Singapore 92
12.1 Registration Process and Regulations 92
12.2 Market Characterization and Forecasts 93
12.3 Cost of Vaccination 94
12.4 Vaccination Pattern 95
12.4.1 Population 95
12.4.2 Vaccinated Population Contribution 96
12.4.3 Vaccination Coverage 97
12.4.4 Number of Doses per Person 97
12.4.5 Total Number of Doses 98
12.4.6 Dose Contribution 98
12.5 Competitive Landscape 99
12.6 Drivers and Barriers 100
12.6.1 Drivers 100
12.6.2 Barriers 100
13 Seasonal Influenza Vaccine Market in Asia-Pacific – Taiwan 101
13.1 Registration Process and Regulations 101
13.2 Market Characterization and Forecasts 103
13.3 Cost of Vaccination 104
13.4 Vaccination Pattern 105
13.4.1 Population 105
13.4.2 Vaccinated Population Contribution 106
13.4.3 Vaccination Coverage 107
13.4.4 Number of Doses per Person 107
13.4.5 Total Number of Doses 108
13.4.6 Dose Contribution 108
13.5 Competitive Landscape 109
13.6 Drivers and Barriers 110
13.6.1 Drivers 110
13.6.2 Restraints 110
14 Seasonal Influenza Vaccine Market in Asia-Pacific – Pipeline Analysis 111
14.1 Pipeline Analysis by Phase 111
14.2 Product Profiles of Promising Molecules 116
14.2.1 Optaflu 117
14.2.2 GSK2186877A 117
14.2.3 Intanza/Flu-ID 118
14.2.4 Fluad Pediatric 119
14.2.5 FluBlok 119
14.3 Product Profiles of Marketed Products 120
14.3.1 Fluarix 120
14.3.2 Vaxigrip 120
14.3.3 Influvac 120
14.3.4 Fluvax 120
14.3.5 Agrippal 120
15 Seasonal Influenza Vaccine Market in Asia-Pacific – Competitive Landscape 121
15.1 Sanofi Pasteur 121
15.2 GlaxoSmithKline Biologicals 121
15.3 Abbott Laboratories (Solvay Pharmaceuticals) 121
15.4 CSL Biotherapies 121
15.5 Novartis Vaccines 122
15.6 Crucell N.V. (Berna Biotech) 122
16 Seasonal Influenza Vaccine Market in Asia-Pacific – Strategic Consolidations 123
16.1 Overview 123
16.2 Major Merger and Acquisition Deals, 2007–2012 123
16.2.1 AstraZeneca Acquires Medimmune 124
16.2.2 Sanofi-Aventis (now Sanofi) Acquires Acambis 124
16.2.3 Mymetics Acquires Virosome Biologicals 124
16.2.4 Simcere Pharmaceutical Acquires a Majority Stake in Jiangsu Yanshen Biological Technology Stock 124
16.2.5 Novartis Completes Acquisition of 85% Stake in Zhejiang Tianyuan 125
16.2.6 Abbott Laboratories Acquires Solvay Pharmaceuticals 125
16.2.7 Nutri Pharma Acquires a Majority Stake in Bionor Immuno 125
16.2.8 Johnson & Johnson Acquires Crucell 125
16.2.9 GlaxoSmithKline to Acquire Remaining Interest in Shenzhen GSK-Neptunus Biologicals 125
16.3 M&A Deals by Geography 126
16.4 Major Licensing Agreements, 2007–2012 127
16.4.1 Crucell Enters into License Agreement with Adimmune Corporation 127
16.4.2 MedImmune Enters into Licensing Agreement with Sanofi Pasteur 127
16.4.3 Vivalis Enters into Licensing Agreement with GlaxoSmithKline 127
16.4.4 Vivalis Enters into Licensing Agreement with Nobilon International 127
16.4.5 MedImmune Enters into Licensing Agreement with GlaxoSmithKline 127
16.4.6 Hemispherx Biopharma Enters into Licensing Agreement with Biken 128
16.4.7 MedImmune Enters into Licensing Agreement with Biken 128
16.4.8 MedImmune Enters into Licensing Agreement with Omninvest 128
16.4.9 OPKO Health Enters into Licensing Agreement with Academia Sinica 128
16.4.10 Altravax Enters into Licensing Agreement with Maxygen 128
16.4.11 Protein Sciences Expands its Licensing Agreement with UMN Pharma for FluBlok and PanBlok 128
16.4.12 NasVax Extends its Research Agreement with Novartis 129
16.4.13 iBio Enters into Licensing Agreement with G-Con 129
16.5 Licensing Deals by Geography 130
17 Seasonal Influenza Vaccine Market in Asia-Pacific – Appendix 131
17.1 Market Definitions 131
17.2 Abbreviations 131
17.3 Bibliography 132
17.4 Research Methodology 133
17.4.1 Coverage 133
17.4.2 Secondary Research 134
17.4.3 Primary Research 134
17.5 Therapeutic Landscape 135
17.5.2 Market Size by Geography 136
17.6 Geographical Landscape 137
17.7 Pipeline Analysis 137
17.8 Competitive Landscape 137
17.8.1 Expert Panel Validation 137
17.9 Contact Us 137
17.10 Disclaimer 137